Technology And Equipment Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V with the Active Ingredient Testosterone Enanthate + Undecanoate in the Dosage Form Ilo

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V with the Active Ingredient Codeine in the Dosage Form Tei

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V with the Active Ingredient Dimethyl Fumarate

Open House Contracts 2024-3

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion Within the Framework of the So-Called Open House Procedure.

Open House Discount Agreements 2024-04 - Rivaroxaban

Open House Originals Discount Agreements 2024-07 - Dapagliflozin

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for Various Active Ingredients/S/Combinations with the Possibility of Conclusion at any Time as Part of the So-Called Open House Procedure

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Dupilumab (D11ah05) as Part of a So-Called Open House Model.

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Brinzolamide + Brimonidine, Atc S01ec24 for the Period September 1St, 2024 - August 31St, 2026